Safety Study of BMS-823778 in Subjects With Hypercholesterolemia

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Dyslipidemia
Interventions
DRUG

BMS-823778

Capsules, Oral, 2 mg, once daily, 28 days

DRUG

BMS-823778

Capsules, Oral, 10 mg, once daily, 28 days

DRUG

BMS-823778

Capsules, Oral, 20 mg, once daily, 28 days

DRUG

Placebo

Capsules, Oral, 0 mg, once daily, 28 days

Trial Locations (12)

4021

Local Institution, Brisbane

23294

National Clinical Research - Richmond, Inc., Richmond

23502

National Clinical Research - Norfolk, Inc., Norfolk

45219

Sterling Research Grp, Ltd., Cincinnati

66219

Pra International, Lenexa

72201

Osborne Research Center, Little Rock

78229

Cetero Research - San Antonio, San Antonio

R2V 4W3

Local Institution, Winnipeg

A1N 1W7

Local Institution, Mount Pearl

N6A 5R8

Local Institution, London

J2B 7T1

Local Institution, Drummondville

H3J 2V5

Local Institution, Montreal

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT01112423 - Safety Study of BMS-823778 in Subjects With Hypercholesterolemia | Biotech Hunter | Biotech Hunter